Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.00
Bid: 63.00
Ask: 67.00
Change: -0.50 (-0.76%)
Spread: 4.00 (6.349%)
Open: 65.50
High: 65.50
Low: 65.00
Prev. Close: 65.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Contract

1 Jun 2005 07:00

Torex Retail PLC01 June 2005 1 June 2005 Torex Retail plc Petroleum & Convenience Division Announces Somerfield Contract Win Torex Retail, a leading provider of IT solutions to major European retailers,today announces that it has won a two year, £3.3 million order with Somerfieldto implement its market leading PoS solution 'Iridium' and back office system 'Prism' into 225 stores across the UK. The solution will be rolled out to both convenience and petrol conveniencesites, including the newly announced stores to be acquired by Somerfield fromTexaco and Fuelforce. Both Iridium and Prism are highly functional, easy to useand can be seamlessly integrated into the Somerfield head office. Commenting on the decision to award the contract to Torex Retail, Tom Scott ofSomerfield said; "Torex Retail was able to provide us with a fully integrated and highlyfunctional solution which is already well proven within the Petroleum &Convenience marketplace. I believe that the overall roll out of the solutionwill increase the overall operating efficiency and profitability of our stores". Chris Moore, CEO of Torex Retail, said: "Our Petroleum and Convenience ('P&C') products are the market leaders in the UKand this win further strengthens our position within the P&C sector. We areconfident that through the combination of both our P&C PoS solution 'Iridium'and our back office system 'Prism', Somerfield's convenience and petrolconvenience stores will be able to achieve substantial operating efficienciesand tangible benefits in the future". Ends Enquiries:Chris Moore, CEORichard Thompson, Group Finance DirectorTorex Retail plcTel: 0870 050 9900 Or Seb Hoyle / Ginny PulbrookCitigate Dewe RogersonTel: 020 7638 9571 About Somerfield Somerfield is a high street retailer offering high quality groceries - with aparticular emphasis on fresh foods. Its stores offer a modern retail environmentwith the latest in-store facilities and a comprehensive range of products inconvenient neighbourhood locations. In the current competitive food retail market Somerfield has focused on itsclear strength in providing shoppers with an easy alternative to the largerout-of-town supermarkets, while maintaining its commitment to fresh qualityfoods. The Somerfield Convenience Brand, Essentials, operates 93 forecourts andConvenience Stores and with the addition of the Texaco and Fuelforceacquisitions that have been announced, the portfolio will increase to 233 by theend of July. About Torex Retail plc - www.torexretail.com Torex Retail plc is a leading independent provider of retail technologysolutions to many of the UK and Europe's leading retailers. In Spring 2004 thecompany was bought out from healthcare software provider Torex plc andre-floated on London's Alternative Investment Market with a marketcapitalisation of more than £100m. Torex's Retail's product and solution setspans high street and out-of-town retail and the petroleum and conveniencesectors and the company's customers include Dixons, Woolworth, Selfridges, Shelland Argos. The company's products cover PoS and a range of in-store and headoffice, loss prevention, logistics and performance and productivity solutions.Torex Retail has more than 1,000 staff based in the UK, Germany, Benelux andEire. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.